OMGA Live signals | Maximize Profits with Getagraph.com

SELL 101900 min ago

@ $3.97

Issued: 14 Feb 2024 @ 09:30

Return: -41.31%

Previous signal: Feb 13 - 09:30

Previous signal: Buy

Return: 1.28 %

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

Stats
Today's Volume	195 162
Average Volume	453 140
Market Cap	128.51M
EPS	$0 ( 2024-03-27 )
Next earnings date	( $-0.400 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.290
ATR14	$0.00700 (0.30%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-07	Mccauley Thomas	Buy	125 000	Stock Option (Right to Buy)
2024-02-07	Mccauley Thomas	Buy	75 000	Stock Option (Right to Buy)
2024-02-07	Karande Mahesh	Buy	314 326	Stock Option (Right to Buy)
2024-02-07	Karande Mahesh	Buy	209 551	Stock Option (Right to Buy)
2024-02-07	Moore Yan	Buy	110 000	Stock Option (Right to Buy)

INSIDER POWER
98.70
Last 90 transactions
Buy: 34 429 434 \| Sell: 15 655 033

Volume Correlation

Long: -0.27 (neutral)

Short: 0.46 (neutral)

Signal:(55.44) Neutral

Omega Therapeutics, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Omega Therapeutics, Inc. Correlation - Currency/Commodity

-0.58
( weak negative )

-0.21
( neutral )

0.00
( neutral )

0.42
( neutral )

-0.11
( neutral )

Omega Therapeutics, Inc. Financials

Annual	2023
Revenue:	$3.09M
Gross Profit:	$-3.68M (-118.84 %)
EPS:	$-1.800

Q4	2023
Revenue:	$989 000
Gross Profit:	$-792 000 (-80.08 %)
EPS:	$-0.370

Q3	2023
Revenue:	$831 000
Gross Profit:	$-1.03M (-124.31 %)
EPS:	$-0.400

Q2	2023
Revenue:	$759 000
Gross Profit:	$-1.06M (-139.66 %)
EPS:	$-0.540

Financial Reports:

No articles found.

Omega Therapeutics, Inc.

Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company. Its OMEGA Epigenomic Programming platform is designed to coopt nature's operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. The company is developing omega epigenomic controller (OEC) candidates to up-regulate the expression of HNF4a, a transcriptional master regulator as a potential way to restore liver-cell function in patients suffering from chronic liver diseases; to control the expression of genes that have been strongly linked to cell-growth inhibition in patients with diabetes and other conditions to restore the capacity for corneal regeneration; to down-regulate expression of the CXCL1, 2, 3, and IL-8 gene cluster; to control expression of genes implicated in patients with idiopathic pulmonary fibrosis to halt or reverse disease progression and improve disease outcomes; to down-regulate the expression of SFRP1, a protein that inhibits hair growth; and to treat non-small cell lung cancer and small cell lung cancer. It is also developing OTX-2002 to down-regulate c-Myc, an oncogene. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.